Skip to main content
. 2005 Jan 27;64(8):1180–1185. doi: 10.1136/ard.2004.033399

Figure 3.

Figure 3

 Association between MTX PGs, pharmacogenetic index, and the physician's assessment of patient's response to MTX. Patients having RBC MTX PG levels <60 nmol/l were 4.4-fold (95% CI 2.0 to 8.5; p = 0.0001) more likely to present a physician's assessment of patient's response to MTX VAS >2 cm (poor response). A lower pharmacogenetic index was also associated with a higher likelihood of physician's assessment of patient's response to MTX VAS >2 cm (p = 0.034). Probability (95% CI) is given.